insights_auto
Por qué ha subido DRUG 4,87%?
Profundizarchevron_right
DRUG:CNSX
Bright Minds Biosciences Inc
77,10 CAD
arrow_upward
+4,87%(+3,58) 1 d
9 oct, 16:00:00 GMT-4 · CAD
search
Todos los símbolos
| Símbolo | Precio | Cambio | % de cambio |
|---|
insights_autoGenerando estadísticas principales de DRUG...
Abrir
76,13 CAD
Alto
77,76 CAD
Bajo
76,13 CAD
Cap. burs.
760,52 M
Vol. medio
865,00
Volumen
400,00
Máximo en 52 sem.
170,00 CAD
Mínimo en 52 sem.
68,02 CAD
BPA
-2,90 CAD
N.º de empleados
26
Abrir
76,13 CAD
Alto
77,76 CAD
Bajo
76,13 CAD
Cap. burs.
760,52 M
Vol. medio
865,00
Volumen
400,00
Máximo en 52 sem.
170,00 CAD
Mínimo en 52 sem.
68,02 CAD
BPA
-2,90 CAD
N.º de empleados
26
Noticias
De fuentes web y partners de noticias
kalkine.ca
·
hace 2 días
Bright Minds Biosciences Stock Faces Downside Pressure as Bearish Momentum Weighs on Investor Sentiment
https://www.dars.gov.et/
·
hace 1 semana
Bright Minds Biosciences (DRUG) Edges Higher: Shares Climb 3.01% to $50.69 - Watchlist Stock Ideas
Perfil
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
Acerca de Bright Minds Biosciences Inc